Lila Sciences' already impressive $235 million first round financing has continued to build and has now closed at $350 million, signalling strong investor interest in its AI-powered, autonomous lab ...

Will scientists be the next to see their profession disrupted by the rise of artificial intelligence? A Cambridge startup could make it happen, by combining AI with robots to build a system that might ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Lila Sciences is hiring dozens ...

Fresh off the closing of a $350 million funding round, artificial intelligence startup Lila Sciences is leasing 244,000 square feet at IQHQ’s Alewife Park laboratory campus in Cambridge. It’s one of ...

She was praised by fans for showing off her medical devices for type 1 diabetes LILA Moss looks just like mum Kate in new sizzling underwear snaps. Fresh off of the Victoria’s Secret catwalk, Lila, 23 ...

Flagship Pioneering’s Lila Sciences has had little trouble finding supporters for its “scientific superintelligence” mission since its March debut. After closing a $235 million series A last month, ...

(Reuters) -AI startup Lila Sciences has raised $115 million in an extension funding round from investors including Nvidia's venture arm, lifting its valuation to more than $1.3 billion, the company ...

Lila Sciences team includes (from left to right) George Church, chief scientist; Chris Fussell, president of operations; Molly Gibson, president of future science; John Gregoire, SVP of materials ...

The news that pro-life activist Lila Rose was declared the winner by students attending a debate earlier this week with an abortion activist at Yale University — a campus not particularly known for ...

Flagship Pioneering’s Lila Sciences has landed a substantial $235 million series A as it looks to exceed the current limits of the drug discovery process through automation. The round, which more than ...

Lila Biologics, a startup that spun out of Nobel Laureate David Baker’s lab at the University of Washington, announced a collaboration with pharmaceutical giant Eli Lilly to develop therapies for ...